Aligos Banks $25M in Strategic China Deal for a New Hepatitis B Attack

SOUTH SAN FRANCISCO, CA – July 06, 2026 – In a move that underscores the strategic importance of the Chinese market for global biotech, Aligos Therapeutics has secured a significant financial and regulatory victory for its lead chronic Hepatitis B (HBV) candidate. The company announced it has received a $25 million upfront payment from Xiamen Amoytop Biotech, cementing an exclusive licensing deal for its drug, pevifoscorvir sodium, in Greater China.

This isn't just a simple licensing transaction; it's a multi-layered strategic play. The deal is amplified by the simultaneous announcement that Chinese regulators have granted the drug Breakthrough Therapy Designation (BTD), a coveted status that promises to accelerate its path to a market where over 90 million people live with the virus. For Aligos, the combination of non-dilutive capital, a powerful local partner, and a regulatory fast-track provides a powerful validation of its science and its go-to-market strategy.

The Financial Architecture of Ambition

For a clinical-stage biopharmaceutical company like Aligos (NASDAQ: ALGS), cash is king. The $25 million upfront payment from Amoytop provides a welcome infusion of non-dilutive capital, meaning the company raises funds without issuing new stock and diluting existing shareholders. According to company projections, this payment helps extend its financial runway into the fourth quarter of 2026, a critical lifeline that allows it to continue its ambitious research and development activities.

But the upfront cash is just the beginning. The deal's structure reveals a much larger long-term value proposition. Aligos is eligible to receive up to an additional $420 million tied to specific clinical, regulatory, and sales milestones. Layered on top are tiered, high single-digit royalties on net sales should pevifoscorvir sodium gain approval and find commercial success in Amoytop’s territories. This structure allows Aligos to de-risk its expansion into China by offloading the high costs of local development onto its partner while retaining significant upside potential.

“We are pleased to provide this update on the collaboration with Amoytop,” stated Lawrence Blatt, Ph.D., M.B.A., Chairman, President, and Chief Executive Officer of Aligos Therapeutics. “The joint steering committee has been formed, Breakthrough Therapy Designation has been granted for pevifoscorvir sodium in China, and we look forward to the continued progression of this program.”

Critically, Aligos retains full development and commercialization rights in all other major markets, including the United States, Europe, and Japan. This “hub-and-spoke” model—securing a strong regional partner for a specific territory while keeping the most lucrative markets for itself—is a hallmark of savvy biotech strategy, maximizing global reach while minimizing capital expenditure.

China's 'Breakthrough' Designation: More Than Just a Label

The granting of Breakthrough Therapy Designation by China's National Medical Products Administration (NMPA) is arguably as significant as the financial terms. Since launching its BTD program in 2020 as part of sweeping regulatory reforms, China has created a powerful incentive for developers of innovative drugs that address serious diseases.

This designation is far more than a gold star. It unlocks a suite of tangible benefits designed to shave months, if not years, off the traditional drug approval timeline. Pevifoscorvir sodium is now eligible for priority review, intensive guidance from regulators at the Center for Drug Evaluation (CDE), and more frequent technical consultations. Perhaps most importantly, it allows for a “rolling submission” of the New Drug Application (NDA), where Aligos and Amoytop can submit completed sections of their application for review rather than waiting for the entire dossier to be finished. This iterative process is designed to identify and resolve potential issues early, smoothing the path to final approval.

This regulatory fast-track is a direct reflection of China's strategic push to move from a market of generics to a hub of global pharmaceutical innovation. For a disease like chronic Hepatitis B, which represents a massive public health burden in China, the NMPA's willingness to accelerate promising therapies signals a clear priority.

The Science: Targeting the Root of Chronic Infection

Behind the financial and regulatory maneuvers lies the core innovation: the drug itself. Pevifoscorvir sodium is an oral small molecule known as a capsid assembly modulator (CAM-E). It represents a new line of attack against a virus that has proven stubbornly difficult to eradicate.

Current standard-of-care treatments, primarily nucleos(t)ide analogues (NAs), are effective at suppressing the virus but rarely achieve a “functional cure.” This is because they fail to eliminate the viral stronghold: a reservoir of covalently closed circular DNA (cccDNA) that persists within the nucleus of infected liver cells. This cccDNA acts as a permanent template for producing new viruses, forcing most patients into lifelong therapy.

This is where pevifoscorvir sodium aims to change the game. It employs a dual mechanism that not only inhibits the assembly of new viral capsids but is also designed to reduce the cccDNA reservoir. By targeting the very foundation of chronic infection, the drug holds the potential to deliver a finite treatment course that leads to a sustained cure—the holy grail of HBV therapy.

Phase 1 clinical data has been encouraging, showing the drug to be safe and well-tolerated while demonstrating potent viral suppression. The ongoing Phase 2 B-SUPREME study, which compares it against a current standard of care, will be a crucial test of its long-term efficacy, with key data expected in the coming year.

A Powerful Partnership for a Formidable Foe

Aligos's choice of partner is as strategic as the deal's terms. Xiamen Amoytop Biotech is not just any local distributor; it is a dominant force in China's hepatology market. As the leading provider of pegylated interferon for chronic HBV in Mainland China and having recently secured approval for PEGBING®, a functional cure for HBV, Amoytop possesses deep clinical, regulatory, and commercial expertise in the field.

This partnership is also an expansion of an existing relationship. The two companies are already collaborating on another HBV candidate, an antisense oligonucleotide (ASO) known as ALG-170675, which Amoytop plans to advance into clinical trials in China this quarter. This deepening alliance creates a powerful combination therapy pipeline, potentially allowing for tailored treatments that attack the virus from multiple angles.

In a crowded and competitive race to develop a functional cure for HBV, with giants like Gilead and GSK also fielding novel candidates, this strategic alliance in the world's largest HBV market gives Aligos a crucial advantage. The combination of innovative science, significant non-dilutive funding, and a well-chosen local champion positions pevifoscorvir sodium as a serious contender in the quest to conquer one of the world's most persistent viral diseases.